News

Somantix B.V.

SomantiX B.V. is a Dutch biotech company focusing on the identification and development of new angiogenesis inhibitors for the treatment of solid cancers through targeting of tumor blood vessels.
Somantix’ screening platform in combination with the binder generation technologies allows validation of new therapeutic targets and development of new cancer medicines.   

 

 

SomantiX B.V.

Life Science Incubator
Yalelaan 62
3584 CM  Utrecht
The Netherlands                                                                                                              

T.    +31(0)30-7600976                                                                                                  

Email: postel@somantix.com